Aptevo Therapeutics : October 11, 2021 Investor Presentation
APVO
11 October 2021
Aptevo Therapeutics
A Leading Bispecific Antibody Company
NASDAQ: APVO
Forward-Looking Statements
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, advancement of its clinical trials and its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "optimism," "potential," "designed," "engineered," "breakthrough," "innovative," "innovation," "promising," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward- looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, and political conditions. For instance, actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including the uncertainties inherent in the initiation and enrollment of future clinical trials, including availability of patients meeting enrollment criteria, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, actions of activist stockholders, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19). These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of publication of this presentation, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.
Aptevo™, ADAPTIR™ and any and all Aptevo Therapeutics Inc. brand, product, service, and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo Therapeutics Inc. or its subsidiaries in the United States or other countries. All rightsreserved.
2
Aptevo at-a-Glance
(1)
Data as of May 26, 2021
3
(2)
Active IND, Currently enrolling patients
Experienced Leadership
Senior Management
Marvin White - President & CEO
Emergent Director; Former CFO, St. Vincent's Health; Former Executive Director & CFO, Lilly USA
Jeff Lamothe - SVP, CFO
Former Emergent VP, Finance; Former CFO, Cangene
Corporation
Fatih Uckun M.D. Ph.D. - Consultant and Chief Clinical Advisor
Former Stohlman Scholar of Leukemia Society of America; Former Professor at USC and UM; Member ASCI
Jane Gross, Ph.D. - Consultant and CSO
Former Emergent VP, Research/Non-Clinical Development; Former VP Immunology Research ZymoGenetics Inc.
SoYoung Kwon - SVP, GC, Corporate Affairs &
HR
Former SVP, GC and Corporate Secretary, AGC Biologics
Daphne Taylor- VP, Finance
Former Chief Financial Officer at BioLife Solutions, VP, Chief Accounting Officer & Controller at Cardiac Science Corporation
Board of Directors
Marvin White
Emergent Director; Former CFO, St. Vincent's Health; Former Executive Director & CFO, Lilly USA
Fuad El-Hibri
Founder, Executive Chairman, Emergent BioSolutions
Daniel Abdun-Nabi
Former President & CEO, COO, Emergent BioSolutions, Former General Counsel, IGEN International, Inc.
Grady Grant, III
Former Vice President of Sales, Tissue Tech Limited; Former Reckitt Benckiser Group; Former Eli Lilly & Co.
Zsolt Harsanyi, Ph.D.
N-Gene Research Labs; Exponential Biotherapies; Porton Int'l
Barbara Lopez Kunz
DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema
John Niederhuber, M.D.
Inova Translational Medicine Institute; National Cancer Institute; Johns Hopkins University
Extensive R&D, Manufacturing, Commercial
and Financial Expertise and Experience
4
Robust Pipeline: Potential for Multiple Shots on
Goal in Hematologic Malignancies and Solid Tumors
Product/
Technology
Potential
Pre-
Clinical Development Stage
Marketed
Milestones/Highlights
Candidate
Indications
Clinical
Phase
Phase
Phase
Target
I
II
III
APVO436
Redirected T cell
Phase 1 dose escalation
AML/MDS
reported positive results;
Cytotoxicity
CD3/CD123
Part 2 dose expansion
(RTCC)
active and recruiting
ALG.APV-527*
T cell
Solid
Advancing into clinical
development in solid
4-1BB/5T4
Co-Stimulation
Tumors
tumors expressing 5T4
APVO603
Dual T cell
Solid
Unique asset for use in
solid tumors, APVO603
4-1BB/OX40
Co-stimulation
Tumors
lead candidate identified
APVO442
Redirected T cell
Prostate
Low affinity CD3,
PSMA/CD3
Cytotoxicity
Cancer
advancing lead candidate
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
Aptevo Therapeutics Inc. published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 October 2021 18:11:01 UTC.